The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Interleukin-6 induces cellular insulin resistance in hepatocytes.
Open accessAbstract
Interleukin (IL)-6 is one of several proinflammatory cytokines that have been associated with insulin resistance and type 2 diabetes. A two- to threefold elevation of circulating IL-6 has been observed in these conditions. Nonetheless, little evidence supports a direct role for IL-6 in mediating insulin resistance. Here, we present data that IL-6 can inhibit insulin receptor (IR) signal transduction and insulin action in both primary mouse hepatocytes and the human hepatocarcinoma cell line, HepG2. This inhibition depends on duration of IL-6 exposure, with a maximum effect at 1-1.5 h of pretreatment with IL-6 in both HepG2 cells and primary hepatocytes. The IL-6 effect is characterized by a decreased tyrosine phosphorylation of IR substrate (IRS)-1 and decreased association of the p85 subunit of phosphatidylinositol 3-kinase with IRS-1 in response to physiologic insulin levels. In addition, insulin-dependent activation of Akt, important in mediating insulin's downstream metabolic actions, is markedly inhibited by IL-6 treatment. Finally, a 1.5-h preincubation of primary hepatocytes with IL-6 inhibits insulin-induced glycogen synthesis by 75%. These data suggest that IL-6 plays a direct role in insulin resistance at the cellular level in both primary hepatocytes and HepG2 cell lines and may contribute to insulin resistance and type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“consistent with previous studies that indicate IL-6 promotes hepatic insulin resistance through IL-6/STAT3induced inhibition of insulin receptor signaling 18,45,46”
From Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis (2024) · cites this paper as [45]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“genes reported to be involved in hepatic insulin resistance, including Il6 45-48 , Spp1 49,50 and Igfbp1 51”
From Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis (2024) · cites this paper as [45]
In the citing paper
“In cultured hepatocytes (25)(26)(27)(28), preadipocytes, and mature adipocytes (29), IL-6 directly impairs insulin action.”
From Signaling Specificity of Interleukin-6 Action on Glucose and Lipid Metabolism in Skeletal Muscle (2006) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
Pradhan, A. D. (2001) · JAMA · doi:10.1001/jama.286.3.327 · Cited by 4,433
Hotamisligil, G. S., Peraldi, P., Budavari, A., Ellis, R., White, M. F., & Spiegelman, B. M. (1996) · Science · doi:10.1126/science.271.5249.665 · Cited by 2,630
Protection from obesity-induced insulin resistance in mice lacking TNF-α function
Uysal, K. T., Wiesbrock, S. M., Marino, M. W., & Hotamisligil, G. S. (1997) · Nature · doi:10.1038/39335 · Cited by 2,234
A family of cytokine-inducible inhibitors of signalling
Starr, R., Willson, T. A., Viney, E. M., Murray, L. J. L., Rayner, J. R., Jenkins, B. J., Gonda, T. J., Alexander, W. S., Metcalf, D., Nicola, N. A., et al. (1997) · Nature · doi:10.1038/43206 · Cited by 2,066
Subcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor-α,in Vivo1
Mohamed‐Ali, V., Goodrick, S., Rawesh, A., Katz, D. R., Miles, J. M., Yudkin, J. S., Klein, S., & Coppack, S. W. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.12.4450 · Cited by 2,032
Yuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li, Z.-W., Karin, M., & Shoelson, S. E. (2001) · Science · doi:10.1126/science.1061620 · Cited by 1,884
Kern, P. A., Ranganathan, S., Li, C., Wood, L., & Ranganathan, G. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.280.5.e745 · Cited by 1,883
Pickup, J. C., Mattock, M. B., Chusney, G. D., & Burt, D. J. (1997) · Diabetologia · doi:10.1007/s001250050822 · Cited by 1,246
Tumor necrosis factor alpha inhibits signaling from the insulin receptor.
Hotamışlıgil, G. S., Murray, D. L., Choy, L., & Spiegelman, B. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.4854 · Cited by 1,220
Interleukin-6-deficient mice develop mature-onset obesity
Wallenius, V., Wallenius, K., Ahrén, B., Rudling, M., Carlsten, H., Dickson, S. L., Ohlsson, C., & Jansson, J.-O. (2002) · Nature Medicine · doi:10.1038/nm0102-75 · Cited by 1,213
Aguirre, V., Werner, E. D., Giraud, J., Lee, Y. H., Shoelson, S. E., & White, M. F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m101521200 · Cited by 1,010
Hotamisligil, G. S., Budavari, A., Murray, D., & Spiegelman, B. M. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117495 · Cited by 819
Prevention of fat-induced insulin resistance by salicylate
Kim, J. K., Kim, Y.-J., Fillmore, J. J., Chen, Y., Moore, I., Lee, J., Yuan, M., Li, Z. W., Karin, M., Perret, P., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11559 · Cited by 737
Subcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor- , in Vivo
Mohamed-Ali, V. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.12.4196 · Cited by 717
Rui, L., Aguirre, V., Kim, J. K., Shulman, G. I., Lee, A., Corbould, A. M., Dunaif, A. E., & White, M. F. (2001) · Journal of Clinical Investigation · doi:10.1172/jci10934 · Cited by 611
Muscle‐derived interleukin‐6: possible biological effects
Pedersen, B. K., Steensberg, A., & Schjerling, P. (2001) · The Journal of Physiology · doi:10.1111/j.1469-7793.2001.0329c.xd · Cited by 599
Plasma interleukin-6, tumour necrosis factor α and blood cytokine production in type 2 diabetes
Pickup, J. C., Chusney, G. D., Thomas, S. M., & Burt, D. (2000) · Life Sciences · doi:10.1016/s0024-3205(00)00622-6 · Cited by 566 · cited 2×
“Of these proinflammatory cytokines, IL-6 has been shown to have the strongest correlation with insulin resistance and type 2 diabetes (5,9,10).”
BackgroundPerreault, M., & Marette, A. (2001) · Nature Medicine · doi:10.1038/nm1001-1138 · Cited by 550
Amino Acid and Insulin Signaling via the mTOR/p70 S6 Kinase Pathway
Tremblay, F., & Marette, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106703200 · Cited by 547
Feinstein, R., Kanety, H., Papa, M. Z., Lunenfeld, B., & Karasik, A. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)74276-8 · Cited by 545
SOCS-3 Is an Insulin-induced Negative Regulator of Insulin Signaling
Emanuelli, B., Peraldi, P., Filloux, C., Sawka‐Verhelle, D., Hilton, D. J., & OBBERGHEN, E. V. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.21.15985 · Cited by 468
SOCS: physiological suppressors of cytokine signaling
Krebs, D. L., & Hilton, D. J. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.16.2813 · Cited by 463
Emanuelli, B., Peraldi, P., Filloux, C., Carine Chavey, A., Freidinger, K., Hilton, D. J., Hotamışlıgil, G. S., & OBBERGHEN, E. V. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104602200 · Cited by 449
Klaunig, J. E., Goldblatt, P. J., Hinton, D. E., Lipsky, M. M., Chacko, J., & Trump, B. F. (1981) · In Vitro Cellular & Developmental Biology - Plant · doi:10.1007/bf02618288 · Cited by 404
Dose-Dependent Effects of Recombinant Human Interleukin-6 on Glucose Regulation
Tsigos, C., Papanicolaou, D. A., Kyrou, I., Defensor, R., Mitsiadis, C. S., & Chrousos, G. P. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.12.4422 · Cited by 324 · cited 2×
“IL-6 has been shown to increase blood glucose through elevated hepatic glucose output (15,16).”
BackgroundTanti, J., Grémeaux, T., OBBERGHEN, E. V., & MARCHAND‐BRUSTEL, Y. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37568-3 · Cited by 308
Suppressors of Cytokine Signaling-1 and -6 Associate with and Inhibit the Insulin Receptor
Mooney, R. A., Senn, J. J., Cameron, S. J., Inamdar, N. M., Boivin, L. M., Shang, Y., & Furlanetto, R. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010579200 · Cited by 282
Self-citationVentre, J. R., Doebber, T. W., Wu, M. S., MacNaul, K. L., Stevens, K. A., Pasparakis, M., Kollias, G. A., & Moller, D. E. (1997) · Diabetes · doi:10.2337/diab.46.9.1526 · Cited by 275
The cancer anorexia-cachexia syndrome.
Nelson, K. A., Walsh, D., & Sheehan, F. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.1.213 · Cited by 265
Yamada, Y., Webber, E. M., Kirillova, I., Peschon, J. J., & Fausto, N. (1998) · Hepatology · doi:10.1002/hep.510280410 · Cited by 260
Fernández‐Real, J. M., & Ricart, W. (1999) · Diabetologia · doi:10.1007/s001250051451 · Cited by 245
Interleukin-6 gene polymorphism and insulin sensitivity.
Fernández‐Real, J. M., Broch, M., Vendrell, J. J., Gutiérrez, C., Casamitjana, R., Pugeat, M., Richart, C., & Ricart, W. (2000) · Diabetes · doi:10.2337/diabetes.49.3.517 · Cited by 242
TNF-α impairs insulin signaling and insulin stimulation of glucose uptake in C2C12muscle cells
Aguila, L. F. D., Claffey, K. P., & Kirwan, J. P. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.276.5.e849 · Cited by 235
Kawazoe, Y., Naka, T., Fujimoto, M., Kohzaki, H., Morita, Y., Narazaki, M., Okumura, K., Saitoh, H., Nakagawa, R., Uchiyama, Y., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.2.263 · Cited by 160
Expression of suppressors of cytokine signaling during liver regeneration
Campbell, J. S., Prichard, L., Schaper, F., Schmitz, J., Stephenson-Famy, A., Rosenfeld, M. E., Argast, G. M., Heinrich, P. C., & Fausto, N. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11867 · Cited by 156 · cited 1×
“Interestingly, recent evidence suggests that some of the observed effects of TNF- may be mediated by its ability to induce IL-6 and IL-6 receptor expression in tissues such as the liver and muscle (38,39).”
BackgroundCheung, A., Ree, D., Kolls, J. K., Fuselier, J. A., Coy, D. H., & Bryer‐Ash, M. (1998) · Endocrinology · doi:10.1210/endo.139.12.6336 · Cited by 153
Aguila, L. F. D., Krishnan, R. K., Ulbrecht, J. S., Farrell, P. A., Correll, P. H., Lang, C. H., Zierath, J. R., & Kirwan, J. P. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.279.1.e206 · Cited by 135
Kanemaki, T., Kitade, H., Kaibori, M., Sakitani, K., 平松, 義., Kamiyama, Y., Ito, S., & Okumura, T. (1998) · Hepatology · doi:10.1002/hep.510270515 · Cited by 133
Interleukin-6 Enhances Glucose Transport in 3T3-L1 Adipocytes
Stouthard, J. M., Elferink, R. P. J. O., & Sauerwein, H. P. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.0389 · Cited by 113
Takano, A., Haruta, T., Iwata, M., Usui, I., Uno, T., Kawahara, J., Ueno, E., Sasaoka, T., & Kobayashi, M. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1891 · Cited by 109
Cheung, A. T., Wang, J., Ree, D., Kolls, J. K., & Bryer‐Ash, M. (2000) · Diabetes · doi:10.2337/diabetes.49.5.810 · Cited by 92
Ventre, J., Doebber, T. W., Wu, M., MacNaul, K., Stevens, K., Pasparakis, M., Kollias, G. A., & Moller, D. E. (1997) · Diabetes · doi:10.2337/diabetes.46.9.1526 · Cited by 82
IL-6 is essential in TNF-α-induced fever
Sundgren‐Andersson, A. K., Östlund, P., & Bartfai, T. (1998) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1998.275.6.r2028 · Cited by 69
Augmented Production of Tumor Necrosis Factor-α in Obese Mice
Yamakawa, T., Tanaka, S., Yamakawa, Y., Kiuchi, Y., Isoda, F., Kawamoto, S., Okuda, K., & Sekihara, H. (1995) · Clinical Immunology and Immunopathology · doi:10.1006/clin.1995.1052 · Cited by 68
Balbis, A., Baquiran, G., Bergeron, J. J. M., & Posner, B. I. (2000) · Endocrinology · doi:10.1210/endo.141.11.7774 · Cited by 35
FACTORS INFLUENCING THE EFFECT OF THE SOLUBLE IL-6 RECEPTOR ON IL-6 RESPONSES IN HepG2 HEPATOCYTES
Paysant, J., Blanqué, R., Vasse, M., Soria, C., Soria, J., & Gardner, C. R. (2000) · Cytokine · doi:10.1006/cyto.1999.0649 · Cited by 23
Carbohydrate malabsorption following acarbose administration
Sobajima, H., Mori, M., Niwa, T., Muramatsu, M., Sugimoto, Y., Kato, K., Naruse, S., Kondo, T., & Hayakawa, T. (1998) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199805)15:5 · Cited by 15
Cytokine-mediated differential induction of hepatic activator protein-1 genes
Wang, S., & Evers, B. M. (1998) · Surgery · doi:10.1016/s0039-6060(98)70257-0 · Cited by 8
Making sense of oxygen sensing
Hardin, C. D. (2001) · The Journal of Physiology · doi:10.1111/j.1469-7793.2001.t01-1-00002.x · Cited by 3
Cited by
Sorted by citations
Muscle as an Endocrine Organ: Focus on Muscle-Derived Interleukin-6
Pedersen, B. K., & Febbraio, M. A. (2008) · Physiological Reviews · doi:10.1152/physrev.90100.2007 · Cited by 2,388
Inflammation: the link between insulin resistance, obesity and diabetes
Dandona, P. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.10.013 · Cited by 2,170
Adipose tissue as an endocrine organ
Galić, S., Oakhill, J. S., & Steinberg, G. R. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.08.018 · Cited by 1,654
“In adipocytes nd hepatocytes IL-6 has been demonstrated to inhibit the insulin ignaling pathway by up-regulating SOCS3 expression, which in urn is known to impair insulin-induced insulin receptor and IRS- phosphorylation (Senn et al., 2002, 2003; Rotter et al., 2003). owever, studies demonstrating that IL-6 is release…”
BackgroundVisceral fat adipokine secretion is associated with systemic inflammation in obese humans
Fontana, L., Eagon, J. C., Trujillo, M. E., Scherer, P. E., & Klein, S. (2007) · Diabetes · doi:10.2337/db06-1656 · Cited by 1,417
“The direct secretion of IL-6 into the portal vein has important metabolic consequences because IL-6 stimulates hepatic acute-phase reactant production (18), impairs insulin-mediated glycogenesis (19), and stimulates hepatic gluconeogenesis (20).”
BackgroundChronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes
Zatterale, F., Longo, M., Naderi, J., Raciti, G. A., Desiderio, A., Miele, C., & Beguinot, F. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2019.01607 · Cited by 1,180
Metadata
- Authors
- Senn, J. J., Klover, P. J., Nowak, I. A., & Mooney, R. A.
- Affiliations
- University of Rochester Medicine (US)
- ORCID
- Mooney, Robert A.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2002-12-01
- Volume
- 51
- Issue
- 12
- Pages
- 3391-3399
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2130078845
- Cited by
- 883
- References
- 51
- Citations by year
- 2026: 27 · 2025: 19 · 2024: 22 · 2023: 29 · 2022: 28 · 2021: 41 · 2020: 42 · 2019: 31 · 2018: 31 · 2017: 36 · 2016: 49 · 2015: 46 · 2014: 46 · 2013: 34 · 2012: 39
- FWCI
- 23.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Centers for Disease Control and Prevention (PHS R01 38138)
- U.S. Public Health Service
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- interleukin-6, insulin resistance, hepatocytes, insulin receptor signaling, IRS-1 tyrosine phosphorylation, phosphatidylinositol 3-kinase, p85 regulatory subunit, Akt activation, glycogen synthesis, type 2 diabetes, inflammatory cytokines
- MeSH terms
- Animals, Cell Line, Dose-Response Relationship, Drug, Humans, Insulin, Insulin Resistance, Phosphoproteins, Phosphorylation, Proto-Oncogene Proteins, Receptor, Insulin, Time Factors, Tyrosine, Signal Transduction, Interleukin-6, Protein Serine-Threonine Kinases, Phosphatidylinositol 3-Kinases, Hepatocytes, Proto-Oncogene Proteins c-akt, Mice, Insulin Receptor Substrate Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
